newsfilter
← Earnings
Earnings Releases·

TriSalus Life Sciences — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue rose 11.3% year-over-year to $12.9 million, while gross margins expanded to 86.2% and operating losses narrowed to $7.7 million from $9.0 million in the prior year period.
  • Full-year 2026 revenue guidance was raised to $46 million–$48 million, reflecting 2% to 6% growth over 2025, with management citing a doubled commercial footprint and new reimbursement rates effective January 2027 as key growth drivers.
  • The company secured $41.1 million in cash and equivalents as of September 30, 2026, following a $46.0 million equity offering in Q1 2026, and received FDA clearance for the TriNav Advance device.
  • Future outlook includes plans to explore partnerships for the investigational immunotherapeutic nelitolimod post-Phase 1 completion and the expectation of first multi-center U.S. data from the PROTECT registry in Q1 2027.
Company
TRISALUS LIFE SCIENCES INC
Sector
Healthcare
Industry
Medical Devices